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ABBREVIATION
ACE - Angiotensin converting enzyme
AER - Albumin Excretion rate
ACR - Albumin Creatinine Ratio
AGE - Advanced  glycation  end  products
AGT - Angiotensinogen
AGTR1 - Angiotensin 11 receptor type 1
AGTR2 - Angiotensin 11 receptor 2
ANP - Atrial Natriuretic Peptide
AT II -          Angiotensin II
BP - Bloood Pressure
CAD  - Coronary Artery Disease
ESRD - End Stage Renal Disease
GBM - Glomerular Basement membrane
GFR - Glomerular Filtration Rate
GLUT - Glucose Transporter
IL - Interleukin
LDL - Low Density Lipoprotein
MCP 1 - Monocyte chemoattractant protein 1
TGF-? - Transforming growth factor-?
PCR - Polymerase Chain Reaction
PG - Prostaglandin
PDGF - Platelet Derived Growth factor
VEGF - Vascular endothelial growth factor
PKC - Protein Kinase C
RAAS - Renin Angiotensin Aldosterone System
ROS - Reactive Oxygen Species
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1INTRODUCTION
Type 2 diabetes mellitus is a common metabolic disorder having
an evident genetic component as shown by the strong familial
aggregation and high concordance in twins1,2. Poor glycaemic control,
duration of the disease and blood pressure (BP) leads to the
development of diabetic microvascular complications. Diabetic
nephropathy is a serious microvascular complication of diabetes
mellitus. The pathogenesis is considered to be multifactorial and genetic,
and other factors such as metabolic control and haemodynamic
alterations resulting in systemic and intrarenal hypertension might also
contribute3. However, not all diabetic patients develop renal
complications4. Clustering of diabetic nephropathy in families5,6 and the
large variation in its prevalence among different diabetic populations
suggest the involvement of genetic factors.
The genetic basis of renal complication in diabetes is not clearly
understood but many candidate genes have been shown to be associated
with diabetic nephropathy7-9. Angiotensin converting enzyme(ACE)
plays an important role in the renin-angiotensin aldosterone pathway
and has been studied extensively as a putative mediator of diabetic
nephropathy. This enzyme cleaves the COOH-terminal dipeptide of
angiotensin I to produce angiotensin II in liver and inactivates
2bradykinin in many tissues10,11. Genes encoding components of the
renin-angiotensin system (RAS) are suggested as logical susceptibility
determinants as angiotensin (Ang) II the final product of the RAS
increases intraglomerular capillary pressure causing
glomeulrosclerosis12,13. Studying the ACE gene is supported by clinical
and experimental studies showing that treatment with ACE-inhibitors
prevents and reduces progression of diabetic nephropathy14-16 and
suppresses hepatic glucose production in type 2 diabetic patients17.
ACE  gene  spans  21  Kb  on  chromosome  17  and  is  characterised
by the presence (insertion [I]) or absence (deletion [D]) of a 287 bp Alu
repeat sequence within intron 1618. Although the (I/D) polymorphism is
in  the  intronic  region  of  the  ACE  gene,  this  polymorphism  is  of  a
functional significance as the ACE levels have been shown to be
genetically controlled. Patients homozygous for the II have the lowest
ACE levels whilst patients with DD genotype have the highest
levels19,20.  Conflicting findings in various populations have been
obtained with regard to the role of ACE (I/D) polymorphism in diabetic
nephropathy21-23 and in type 2 diabetes23-25. Ethnic factors might
contribute to variability between reports evaluating the role of ACE
(I/D) polymorphism. In this study, we intended to determine the
distribution of ACE genotypes and its frequency in diabetic patients
with nephropathy.
REVIEW OF
LITERATURE
3REVIEW OF LITERATURE
Diabetic nephropathy is a more common cause of chronic kidney
disease especially in developing countries.
In diabetic patients the presence of persistant microalbuminuria in
the absence of clinical or laboratory evidence of other kidney disease or
renal tract disorders is termed as diabetic nephropathy26.
Diabetic nephropathy is a clinical syndrome characterized by the
following:
? Persistent albuminuria (>300 mg/d or >200 ?g/min) that is
confirmed on at least 2 occasions 3-6 months apart
? Progressive decline in the glomerular filtration rate (GFR)
? Elevated arterial blood pressure
Proteinuria was first recognized in diabetes mellitus in the late
18th century. In the 1930s, Kimmelstiel and Wilson described the
classic lesions of nodular glomerulosclerosis in diabetes associated with
proteinuria and hypertension.
4Pathological changes in Diabetic nephropathy:
The nephropathology in diabetic patients is unique to the disease.
Thickening of the basement membrane is the first change that can be
quantitated. The thickening of the tubular basement membrane parallels
the GBM thickening. Afferent and efferent glomerular artery hyalinosis
can be detected in early stage of diabetes. This can eventuate in  the total
replacement of the smooth muscle cells of these small vessels by waxy,
homogenous translucent appearing periodic acid Schiff(PAS) positive
material consisting of immunoglobulins, complement, fibrinogen,
albumin and other plasma proteins27. Arteriolar hyalinosis, glomerular
capillary subendothelial hyaline and capsular drops along the parietal
surface of the bowman’s capsule make up the so called exudative
lesions of diabetic nephropathy. These lesions are capable of triggering
inflammatory cascades as they can fix heterologous complement26.
Increase in fraction of glomerulus occupied by mesangium can be
documented. The diffuse and generalised process of mesangial
expansion has been termed as diffuse diabetic glomerulosclerosis
(Kimmelsteil Wilson nodular disease) represent areas of marked
mesangial expansion, appearing as large round fibrillar mesangial zones
5with pallisading mesangial nuclei around periphery of the nodule and
extreme compression of associated glomerular capillaries28.
As disease progresses towards renal insufficiency, more glomeruli
become totally sclerosed with complete closure of glomerular capillary
lumens. Various studies suggest that the glomerular and interstitial
changes of diabetes have somewhat different pathogenetic mechanisms
and that advancing interstitial fibrosis generally follows the glomerular
processes in diabetes.
The key change in diabetic glomerulopathy is augmentation of
extracellular matrix. The earliest morphologic abnormality in diabetic
nephropathy is the thickening of the GBM and expansion of the
mesangium due to accumulation of extracellular matrix. The severity of
diabetic glomerulopathy is estimated by the thickness of the peripheral
basement membrane and mesangium and matrix expressed as a fraction
of appropriate spaces (eg, volume fraction of mesangium/glomerulus,
matrix/mesangium, or matrix/glomerulus).
The glomeruli and kidneys are typically normal or increased in
size initially, thus distinguishing diabetic nephropathy from most other
forms of chronic renal insufficiency, wherein renal size is reduced.
6Pathogenesis of diabetic nephropathy:
The simple scheme for the pathogenesis of diabetic nephropathy
is shown in figures 1, 2 and 3.
Since nephropathy does not develop in all diabetic patients,
genetic and hemodynamic factors in addition to hyperglycemia must be
operative in these patients at risk of development of diabetic
nephropathy.
Factors predicting high risk for development of diabetic nephropathy
include:
1. Poor glycemic control.
2.  Hemodynamic injury (systemic and intravascular
glomerular hypertension).
3.  Familial and genetic factors.
4.  Dyslipidemia
1. Hyperglycemia:
 A host of metabolic consequences of hyperglycemia have been
described as an explanation for renal lesions. Hyperglycemia is a crucial
Figure-1
INTERACTION OF HEMODYNAMIC AND METABOLIC PATHWAY,
CYTOKINES AND INTRACELLULAR SIGNALLING MOLECULES MEDIATING
DIABETIC NEPHROPATHY
Figure-2
METABOLIC AND HEMODYNAMIC FACTORS IN DIABETIC NEPHROPATHY
7factor in the development of diabetic nephropathy because of its effects
on glomerular and mesangial cells, but alone it is not causative.
Mesangial cells are crucial for maintenance of glomerular capillary
structure and for the modulation of glomerular filtration via smooth-
muscle activity.
 Hyperglycemia is associated with an increase in mesangial cell
proliferation and hypertrophy, as well as increased matrix production
and basement membrane thickening. In vitro studies have demonstrated
that hyperglycemia is associated with increased mesangial cell matrix
production29,30 and mesangial cell apoptosis31,32.  Mesangial cell
expansion seems to be mediated in part by an increase in the mesangial
cell glucose concentration, since similar changes in mesangial function
can be induced in a normal glucose milieu by overexpression of glucose
transporters, such as GLUT1 and GLUT4, thereby increasing glucose
entry into the cells30.
Hyperglycemia might also upregulate VEGF expression in
podocytes33, which could markedly increase vascular permeability34.
Hyperglycemia, however, does not account fully for the risk of diabetic
nephropathy, as shown by studies in which kidneys from nondiabetic
donors were transplanted into patients with diabetes and nephropathy
Figure 3
SCHEMATIC  REPRESENTATION OF METABOLIC AND HEMODYNAMIC
FACTORS IN DIABETIC NEPHROPATHY
8developed irrespective of the glucose control35. Hyperglycemia might,
therefore, be necessary for but not sufficient to cause renal damage.
Three mechanisms have been postulated that explain how
hyperglycemia causes tissue damage: nonenzymatic glycosylation that
generates advanced glycosylation end products, activation of PKC, and
acceleration of the aldose reductase pathway36,37. Oxidative stress seems
to be a theme common to all three pathways38.
These include
? Polyol pathway:
Hyperglycemia has been proposed to activate polyol pathway in
insulin insensitive tissues. This is suspected to mediate neuropathy,
retinopathy and perhaps nephropathy. The mechanism proposed is
disorder in the cellular myoinositol metabolism due to increased flux of
glucose through the polyol pathway. In addition the pathway may also
provide additional reactive substrates for non enzymatic reactions
involving the proteins which are responsible for vascular
complications39.
9In addition, the increased flux through polyol pathway results in
increased ratio of NADH:NAD+  which appears to be important in the
stimulation of denovo synthesis of diacyl glycerol and subsequently
activation of PKC.
Clinical trials of aldose reductase inhibitors have not shown
beneficial effects in reducing microalbuminuria in humans; however,
research continues in this arena.
? Non – enzymatic glycation:
The advanced glycation end products (AGE) modify the ligands
on extracellular components and interact with cellular receptors to alter
intracellular function.  AGEs likely upregulate a host of genes that can
adversely affect protein structure and function. AGEs also cause
increased cross-linking and reduced breakdown of the thickened
glomerular basement membrane constituents and enhanced binding of
circulating plasma proteins and activation of cells, particularly
macrophages. AGE modified LDL also has impaired clearance40.
AGEs have been shown to correlate with microalbuminuria in
diabetic patients. In a study of low- and high-molecular-weight AGEs in
subjects with and without diabetes, AGE content in arterial wall
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collagen was fourfold higher in diabetes41. Diabetic patients with ESRD
had twice as much tissue AGE as patients without renal disease.
Circulating AGEs were elevated in patients with diabetes compared to
those without diabetes, and the levels correlated directly with creatinine.
Novel drugs such as Aminoguanidine are being evaluated for their
therapeutic benefit in the management of diabetic nephropathy as these
compounds bind preferentially to reactive precursors of AGEs and form
unreactive substituted products that can no longer form cross-links42.
Schematic representation of the possible mechanisms by which
advanced glycation end – products (AGEs) and AGE receptors may
contribute to the pathogenesis of diabetic nephropathy is illustrated in
chart 1.
? Hormones and cytokines:
TGF-?: High ambient glucose seems to promote renal cellular
hypertrophy and matrix accumulation via increased expression of TGF-
? by  the  kidney  (ie.  Glomrular  and  tubular  cells).  It  regulates  cell
hypertrophy and the production of extracellular matrix elements such as
collagen, fibronectin, tenascin, laminins and proteoglycans. They also
promote cell matrix interactions and matrix accumulation. They regulate
Chart- I
AGE AND ITS RELATION WITH DIABETIC NEPHROPATHY
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extra cellular matrix components by upregulating the synthesis of
protease inhibitors and downregulating the synthesis of matrix
degrading proteases. Hyperglycemia also has been  observed to
upregulating signalling receptors for TGF-? in kidney cells43.
Inflammatory cytokines also contribute to the development and
progression of diabetic nephropathy, specifically interleukin 1 (IL-1),
IL-6 and IL-18 and tumor necrosis factor. Concentrations of all these
cytokines were increased in models of diabetic nephropathy and seemed
to affect the disease via multiple mechanisms. In addition, raised levels
of several of these cytokines in serum and urine correlate with
progression of nephropathy, indicated by increased urinary albumin
excretion44.
? PKC:
Hyperglycemia resulting in increased functioning of polyol
pathway results in increased ratio of NADH/NAD+ , this results in
shunting of some glycolytic  intermediates into phsphatidic acid and
diacylglycerol45. This increased synthesis of diacylglycerol causes
activation of  diacylglycerol causes activation of PKC resulting in
increased matrix production. Activation  of  this  enzyme  leads  to
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increased secretion of vasodilatory prostanoids, which contributes to
glomerular hyperfiltration.
PKC leads to increased production of Jun/Fos (AP 1)
transcription factor complex. This factor binds to and activates several
gene promoters including growth factors and matrix molecules. PKC
may also be involved in TGF-? overexpression – as a consensus AP1
binding site and other glucose responsive elements have been identified
in the promoter region of the TGF-?1 gene. By activation of TGF- 1,
PKC  increases production of extracellular matrix by mesangial cells46.
PKC activation induces the activity of mitogen-activated protein kinases
(MAPK) in response to extracellular stimuli through dual
phosphorylation at conserved threonine and tyrosine residues. The
coactivation of PKC and MAPK in the presence of high glucose
concentrations indicates that these two families of enzymes are linked47.
Fig-4 shows pathogenesis of diabetic nephropathy.
? Angiotensin II:
In diabetic nephropathy, the activation of the local renin-
angiotensin system occurs in the proximal tubular epithelial cells,
mesangial cells, and podocytes. Angiotensin II (ATII) itself contributes
Figure-4
METABOLIC PATHWAYS AND ROS IN PATHOGENESIS OF DIABETIC
NEPHROPATHY
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to the progression of diabetic nephropathy. ATII is stimulated in
diabetes despite the high-volume state typically seen with the disease,
and the intrarenal level of ATII is typically high, even in the face of
lower systemic concentrations. Ang II may underlie the altered renal
hemodynamics in diabetics.  ATII preferentially constricts the efferent
arteriole in the glomerulus, leading to higher glomerular capillary
pressures.
Ang II also has additional non-hemodynamic effects, as renal
growth factor and a profibrinogenic agent that stimulates ,matrix
synthesis, at least in part due to stimulation of TGF-? activity48 and
other growth factors. The endothelial cells contain ACE, which converts
Ang I to Ang II.
NO has been shown to downregulate the synthesis of ACE49 in
the endothelium, as well as Ang II type 1 receptors (AT1) in vascular
smooth muscle cells, thus having the potential to decrease Ang II
production and action50,51. ACE inhibitors not only decrease Ang II
synthesis but prevent the degradation of bradykinin, one of the most
important physiological molecules involved in the release of NO52. The
main subtypes of Ang II receptors are AT1 and AT253. AT1 mediates
the vasoconstrictor effect of Ang II and mediates the Ang II–induced
14
growth in cardiovascular and renal tissue52.  NO can downregulate AT1
receptors in vascular tissue50 and mitigate the actions of Ang II54. AT2
actions are less well understood. Figure -5 showing NO and AT II
relationship in diabetic nephropathy.
The fact that ACE inhibitor are renoprotective, strongly suggests
a role of increasing  systemic and intrarenal production of Ang II in
diabetic nephropathy.
? Eicosanoids:
Vasodilatory prostanoids (PGE2, PGI2) contribute to early
glomerular hypertension. There is also evidence of increase in
thromboxane (TXA2) generation, correlating with the development of
proteinuria. In vitro studies have demonstrated increased fibronectin
production by mesangial cells following addition of thromboxane
analogues. It is also known to stimulate TGF-? production in mesangial
cells.
? Other mediators:
? Nitric oxide appears to be a mediator of glomerular
hyperfilteration.
Figure – 5
NITRIC OXIDE AND ANGIOTENSIN II IN DIABETIC NEPHROPATHY
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? Change in cytosolic calcium (increase) has been shown to
participate in the genesis of some of the diabetes
complications ie. Leukocyte and B cell dysfunction57.
2. Glomeular hemodynamics in Diabetic nephropathy:
Patients with diabetes tend to have a greater GFR than
nondiabetics. This hyperfiltration in early diabetes results from increase
in blood flow and a concomitant increase in glomerular capillary
hydraulic pressure58. Possible factors responsible for this may be
increased vasodilatory prostanoids, nitric oxide and humoral
vasodilators (glucagon and ANP)59. Increased sodium reabsorption in
proximal tubules leads to reduced sodium delivery to macula densa and
alters tubuloglomerular feedback. In addition, the glomerular capillary
surface area available for filteration is increased in diabetics and
contributes to increased GFR.
The early increase in glomerular blood flow and glomerular
capillary pressure enhances the shear stress effect on the glomerular
capillary wall and the mesangium. The stess may lead to endothelial
dysfunction, which translates into alterations in GBM structure as well
as mesangial cell dysfunction. Intraglomerular hypertension can
15
? IGF-1 is implicated in diabetic glomerular hypertrophy.
? Elevated PDGF ? and interleukin expression has been
observed in the glomeruli of diabetic rats.
? Hyperglycemia may also cause damage via increased
oxidative stress by promoting reactive oxygen species
production as well as attenuating free radical scavenging
molecules. Hyperglycemia specifically induces oxidative
stress, even before diabetes becomes clinically apparent.
Concentrations of markers of DNA damage induced by
reactive oxygen species are higher in patients with more-
severe nephropathy (i.e. proteinuria versus microalbuminuria).
Furthermore, histological analysis of human kidney biopsy
specimens has detected products of glyco-oxidation (combined
products of glycation and protein oxidation) and lipoxidation
in the mesangial matrix and glomeruli, whereas these lesions
are much less common in specimens from individuals without
diabetes55,56.
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increase the macromolecular trafficking across the mesangium and that
can provoke the mesangial cells to increase their production of
mesangial matrix components60.
Mesangial expansion may be a specific example of how renal ie
particularly glomerular hypertrophy can be disadvantageous. A link may
be present between the intraglomerular hypertension of diabetic
nephropathy and stretch induced production of prosclerotic cytokine –
transforming growth factor beta (TGF-?)61.
According to Steno hypothesis, all the diabetic microvascular
complications are manifestations of increased vascular permeability and
endothelial damage in various organs. This view says that glomerular
endothelial dysfunction with the ensuing disturbance in glomerular
permeability is just one facet of generalised endothelial dysfunction62.
3. Familial and genetic factors:
Genetic susceptibility to diabetic nephropathy has been suggested
on the basis of the observation that only one-third of the individuals
with diabetes ever develop nephropathy, irrespective of glycemic
control. There has also been strong clustering of diabetic nephropathy in
families.
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Polymorphism of ACE gene has received lots of attention in the
above respect. Insertion/Deletion polymorphism in the ACE gene have
been found to predict the severity of disease and rate of progression63.
Polymorphism of apo E has also been found to be associated with
diabetic nephropathy64.
4. Dyslipidemia:
Dyslipidemia has also been found to be associated with
microalbuminuria in many studies65-67.
Proteinuria:
In addition to the risk factors mentioned above , proteinuria itself
causes progression of renal damage. Increased glomerular permeability
will allow plasma proteins to escape into the urine. Some of these
proteins will be taken up by the proximal tubular cells, which can
initiate an inflammatory response that contributes to interstitial scarring
eventually leading to fibrosis. Tubulointerstitial fibrosis is seen in
advanced stages of diabetic nephropathy and is a better predictor of
renal failure than glomerular sclerosis. The excessive tubular
reabsorption of proteins induces the release of vasoactive and
inflammatory cytokines such as Endothelin1, Osteopontin and monocyte
19
chemoattractant protein 1 (MCP 1). These factors in turn cause
overexpression of proinflammatory and fibrotic cytokines and
infiltration of mononuclear cells resulting in injury to
tubulointerstitium68. There is an epithelial-mesenchymal transition that
takes place in the tubules, with proximal tubular cell conversion to
fibroblast-like cells. These cells can then migrate into the interstitium
and produce collagen and fibronectin.
 Even the beneficial effects of ACE inhibitors in diabetic renal
disease, reflects their antiproteinuric action in addition to reduction of
Ang II mediated effects on growth factor activation and glomerular
hemodynamics68.
The present concensus is that all the above mentioned risk factors
contribute to chronic low grade inflammation, which is present in the
diabetic state. This is said to be responsible for endothelial dysfunction
resulting in altered basement membrane synthesis, contributing to
arterial stiffness and increased vascular permability.
Clinical stages of diabetic nephropathy:
20%-30% of patients with Type 2 Diabetes will suffer from
Diabetic Nephropathy, which means that one third of Diabetic patients
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develop into Diabetic Nephropathy. Diabetic nephropathy can be
characterized into different clinical stages which differ with respect to
renal hemodynamics, systemic BP and urinary albumin excretion
rate(AER).
Stage 1: Glomerular ultrafiltration period:
In this period, glomerular filtration rate is very high and patients
have no obvious symptoms  but manifests with renal hypertrophy,
elevated renal blood flow and increased GFR. AER is typically within
normal range. The histopathological changes are potentially reversible
with insulin therapy and stringent glycemic control. Diabetic patients
with extremely high GFR (above 150-170 mL/min) during this stage are
at increased risk of future development of diabetic nephropathy.
Nephropathy is difficult to perceive in this period, so Diabetic patients
must make urine check during less than 6 months.
Stage 2 : Slow development period/Clinical latency/Incipient stage:
The urine microalbuminuria excretion rate increases after doing
exercises and it becomes normal after rest in this period of Diabetic
Nephropathy. Glomerular structure changes in thickening of glomerular
basement membrane and increase of mesentery matrixes.
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Stage 3 : Early Diabetic Nephropathy period/Microalbuminuria:
Typically occurs 5-15 yrs of onset of diabetes. In this period,
blood pressure of patients raised by the influence of Diabetic
Nephropathy and urine microalbuminuria excretion can be decreased
with the falling of blood pressure. Glomerular structure changes
obviously in thickening of glomerular basement membrane and increase
of mesentery matrixes. Histologically diffuse or nodular
glomerulosclerosis as well as early signs of arteriosclerosis and
tubulointerstitial fibrosis is seen. GFR begins to decline. Serum
creatinine may still be in the normal range.
Stage 4 : Clinical Diabetic Nephropathy period/Macroalbuminuria:
A great deal of albumins appears and patients who have urine
protein with more than 3.5g/24h may have the symptoms like
hypoalbuminemia, edema and high blood pressure always with nitrogen
retention and Diabetic eye disease.
Stage 5 : End-stage Renal Failure period:
Urine protein excretion decreased with the failing of the
glomerulus and glomerular filtration rate is less than 10ml/min. In this
22
period of Diabetic Nephropathy, patients present high blood pressure,
hypoalbuminemia, edema, increasing of serum creatinine and urea
nitrogen, anorexia, nausea and vomiting, anemia and some other
symptoms. Secondary Uremia neuropathy and Cardiomyopathy can be
caused by End-stage Renal Failure.
Clinical diagnosis :
Among the earliest changes demonstrable in diabetic nephropathy
is glomerular hyperperfusion. This is accompanied by
microalbuminuria, which serves as a sensitive early indicator of adverse
effects of diabetes on the kidney and is a powerful predictor of the
subsequent course. Clinically, the most important screening tool for
identifying early nephropathy is detection of microalbuminuria. The
prevalence of microalbuminuria in patients with diabetes is 10-30%69.
Microalbuminuria is also a powerful predictor of cardiovascular
disease in both type 1 and type 2 diabetes. In type 2 diabetes,  diabetes
has been present for several years by the time it is diagnosed so annual
microalbuminuria screening should begin at the time of diagnosis.
Several methods are available for screening and give comparable
results. The gold standard is the 24-hour urine collection (normal
23
albumin excretion <30 mg per 24 hours), which, if accompanied by
serum and urine creatinine, also allows calculation of creatinine
clearance rate and serves as a reference for future comparison.
Somewhat more convenient for the patient is the
albumin/creatinine ratio on a spot urine sample (normal <30 mg albumin
per g creatinine) or albumin excretion rate in a timed specimen (4 hours
or overnight, normal <20 mg albumin per min). Measuring albumin
without relating it to a duration of collection or creatinine concentration
is less sensitive and specific because of dilution variability. Several
methods are available for screening and give comparable results.
The gold standard is the 24-hour urine collection (normal albumin
excretion <30 mg per 24 hours), which, if accompanied by serum and
urine creatinine, also allows calculation of creatinine clearance rate and
serves as a reference for future comparison. Somewhat more convenient
for  the  patient  is  the  albumin/creatinine  ratio  on  a  spot  urine  sample
(normal <30 mg albumin per g creatinine) or albumin excretion rate in a
timed specimen (4 hours or overnight, normal <20 mg albumin per min).
Measuring albumin without relating it to a duration of collection or
creatinine concentration is less sensitive and specific because of dilution
variability.
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There is a diurnal variation in urinary protein excretion, with less
glomerular protein leak during nighttime and recumbency. Thus,
measurement on collections of less than 24 hours may show the effect of
time  of  day.  There  is  also  considerable  variation  from  day  to  day,  so
three collections should be carried out over a 6-month period with the
designation of microalbuminuria reserved for those with elevations on
two out of three measurements.
Furthermore, screening should avoid other factors that may
temporarily induce albuminuria, such as poor glycemic control,
exercise, fever, urinary or systemic infections, and marked hypertension.
Both glycemic control and rigorous control of blood pressure
have significant impact on prevention and progression of diabetic
nephropathy70. Identification of patients with microalbuminuria selects a
population of patients with increased mortality. Studies in both type 1
and  type  2  patients  show  that  the  use  of  ACE  inhibitors  leads  to
decreased albumin excretion and may postpone or even prevent overt
nephropathy71.
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ANGIOTENSIN-CONVERTING ENZYME (ACE)
Angiotensin-converting enzyme (ACE) is a zinc metallopeptidase
widely distributed on the surface of endothelial and epithelial cells.
Angiotensinogen is converted to angiotensin I by stimulation of renin.
ACE then converts angiotensin I to angiotensin II, the main active
product of the renin–angiotensin–aldosterone system (RAAS).
The human ACE gene is located on chromosome 17q2372, and
includes 26 exons. The coding sequence codes for a 1306 amino acid
protein, including a single peptide. The gene product, ACE, is composed
of 2 homologous domains with 2 active sites73. The ACE gene product
ACE converts angiotensin I to angiotensin II, and is involved in the
degradation of bradykinin. Bradykinin acts as a potent stimulator of
nitric oxide (NO) release. NO plays a crucial role in protecting the
endothelium from injury. Furthermore, it has been reported that
hypertensive effects are mediated in a bradykinin-dependent manner.
The ACE gene contains a polymorphism in the form of either
insertion (I) or deletion (D) of a 287 base pair Alu repetitive sequence in
intron 1674. This polymorphism is shown to be associated with the
interpersonal variability of ACE levels in circulating blood18. The
Figure  6
Schematic representation of the primary structure of several members of the ACE protein
family. The locations of the active-site zinc-binding motifs are indicated by HEXXH;
transmembrane domains are in black. The sequence of gACE is identical to that of the C
domain  of  sACE,  except  for  its  first  36  residues.  Human  gACE  and  sACE  have  the  same
carboxy-terminal transmembrane and cytosolic sequences, whereas ACE2 has a distinct
transmembrane  and  cytosolic  sequence.  Neither  of  the Drosophila ACEs, AnCE and Acer,
has a membrane-anchoring sequence. Dimensions are not to scale. N, amino terminus; C,
carboxyl  terminus.  The  single  lines  are  regions  of  sequence  with  no  similarity  to  other
proteins. The carboxyl end of ACE2 is homologous to collectin, a non-enzymatic protein
associated with renal injury.
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deletion allele at this gene site is associated with increased plasma ACE
activity. An increased risk of progression of renal disease associated
with the
ACE-D allele has been reported in some populations with renal
disease75,76 but not in others77,78. A genetic predisposition to diabetic
nephropathy based on the DD genotype has been reported in several
studies22,79,80 but remains controversial81
Structure of ACE:
There are two forms of ACE (Fig-6) in humans, encoded by a
single gene located on chromosome 17 at q23; it is 21 kb in length and
contains 26 exons and 25 introns. The longer form, known as somatic
ACE (sACE), is transcribed from exons 1-12 and 14-26, whereas the
shorter form, known as germinal or testicular ACE (gACE), is
transcribed  from  exons  13-26.  The  promoter  for  s  ACE  is  in  the  5'
flanking region of the first exon, whereas that for g ACE is located
within intron 1282. Somatic ACE consists of an intracellular domain, a
transmembrane domain and two similar extracellular domains, the
amino or N domain and the carboxy or C domain.
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The structure of the ACE gene is the result of gene duplication;
the N and C domains are similar in sequence, and the homologous exons
encoding the N and C domains (exons 4-11 and 17-24, respectively) are
very similar in size and have similar codon phases at exon-intron
boundaries. Each of the domains contains a catalytically active site
characterized by a consensus zinc-binding motif (HEXXH in the single-
letter amino-acid code, where X is any amino acid) and a glutamine
nearer the carboxyl terminus that also binds zinc; ACE and its homologs
therefore make up the M2 gluzincin family83.
The X-ray structure(Fig-7)  of testicular ACE, and its complex
with the widely used ACE inhibitor lisinopril, at 2.0 Å resolution has
been elucidated. This structure was determined using the anomalous
scattering of the bound Zn atom at beam line BM14 of the ESRF.The
three-dimensional structure reveales that ACE is composed of a-helices
for the most part, and incorporates a zinc ion and two chloride ions. In
fact it bears little resemblance to carboxypeptidase A except in the
active site zinc-binding motif. Instead, it resembles rat neurolysin and
Pyrococcus furiosus carboxypeptidase, despite sharing little amino-acid
sequence similarity with these two proteins. This similarity extends to
the active site, which consists of a deep, narrow channel that divides the
Figure-7
STRUCTURE OF ACE
28
molecule into two subdomains. On top of the molecule is an amino-
terminal 'lid', which seems to allow only small peptide substrates (2530
amino acids) access to the active site cleft this accounts for the inability
of ACE to hydrolyse large, folded substrates.
The Genes of the RAS:
The genes encoding components of the renin-angiotensin system
(RAS) present attractive candidates for diabetic nephropathy. The RAS
gene system comprises the renin, angiotensinogen (AGT), angiotensin I-
converting enzyme (ACE), and angiotensin II receptor types 1  and  2
(AGTR1, AGTR2) genes. The renin gene maps to chromosome 1q32,
spans approximately 12 kb, and comprises 10 exons and nine introns84,85.
The angiotensinogen gene maps to chromosome 1q42–43, spans
approximately 13 kb, and comprises five exons and four introns86,87;
exons 1 and  5  encode  for  the  5'  and  3'  untranslated  regions  of  mRNA,
respectively. The ACE gene maps to chromosome 17q23(Fig-8), spans
21 kb, and comprises 26 exons and 25 introns88,89. The two major
species of ACE mRNA are a 4.3-kb endothelial-type mRNA
(transcription encompassing exons 1 to 26, excluding exon 13) and a 3-
kb testicular type ACE mRNA (transcription encompassing exons 13 to
26). Exon 26 encodes for the functionally important membrane-
Figure-8
CHROMOSOMAL LOCALISATION OF ACE
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anchoring domain of the  ACE  protein.  The  endothelial  type  of  ACE
mRNA is found not only in endothelial cells, but also in epithelial cells.
The angiotensin II receptor type 1 gene maps to chromosome 3 and the
angiotensin II receptor type 2 gene maps to chromosome X90-92.
Circulating RAS Components
RAS functions as an endocrine system. The renin gene is
expressed primarily in the juxtaglomerular cells of the kidney, where
renin is synthesized, stored, and released into the circulation. Prorenin is
cleaved to form renin, which is stored in tissue granules until it is
released in response to specific secretagogues. Secretion of renin from
the kidneys is controlled by several factors. The macula densa are a
specialized group of distal convoluted tubular cells that act as
chemoreceptors for sodium and chloride levels in the distal tubule.
Sodium retention increases blood volume, which is  followed  by  an
increase in blood pressure. This increase in blood pressure activates a
negative feedback regulation of the juxtaglomerular cells in the kidney,
which sense renal perfusion pressure and renin production are inhibited.
Renin secretion is autonomically modulated via sympathetic innervation
of the renal tubules and arterioles.
Figure-9
ACTIONS   OF ACE
Figure-10
CIRCULATING AND TISSUE FORMS OF ACE
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Circulating renin catalyzes the angiotensinogen-to-angiotensin I
conversion (Fig-9). The angiotensinogen gene is expressed in the liver,
the site of AGT synthesis and release into the circulation. The
angiotensin I (Ang I) generated by renin activity is a vasoinactive
decapeptide. Conversion of angiotensin I to angiotensin II (Ang II) is the
key reaction in the RAS pathway, generating the effector of the system,
Ang II, a potent vasoconstrictor(Fig-10). The reaction is catalyzed by
ACE (kininase II; EC 3.4.15.1), a zinc metallopeptidase member of the
Alu family that functions as a dipeptidyl carboxypeptidase (DCP1). The
mechanisms controlling the circulating ACE levels are less clear than
those for renin. The most likely genetic control is at the level of
transcription and would involve linkage disequilibrium with regulatory
elements of the ACE gene. Once the protein is translated and bound to
the cell membrane, release would require cleavage of the hydrophobic
bonds that anchor the protein to the membrane. ACE cleaves the C-
terminal His-Leu dipeptide from Ang I, generating the vasoactive
octapeptide Ang II93. Further conversion of Ang II to Ang III is possible
by cleavage of the aspartic acid from position 1 of the octapeptide;
however, the generated Ang III is less potent as a vasoconstrictor,
compared to Ang II93. Circulating ACE is found in biological fluids,
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such  as  plasma,  amniotic  and seminal fluids, and originates from
endothelial cells.
ACE also acts as a protease on bradykinin, cleaving the C-
terminal Phe-Arg dipeptide, with the net effect of inactivating this
vasodilator. Therefore, ACE enzymatic activity will result in a double
effect: activation of a vasoconstrictor/pressor (Ang II) agent and
inactivation of  a  vasodilator  agent  (bradykinin).  Ang  II  is  also  an
aldosterone-stimulating peptide. Aldosterone promotes depletion of
potassium while promoting the retention of sodium and water; therefore
Ang II exerts a negative feedback on rennin production due to volume
expansion and/or to a direct effect on juxtaglomerular cells.
Tissue RAS Components
RAS also functions as a paracrine system. Ang II is demonstrated
to be produced in multiple target organs by local RAS pathways.
However, under normal conditions the renin responsible for local Ang I
generation appears to derive from circulation, being of renal origin. The
key component of the tissue RAS, as in circulating RAS, is ACE. At the
cellular level, the ACE molecule projects into the extracellular space and
is anchored to the plasma membrane by the C-terminal hydrophobic
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region that spans the membrane and ends in a short cytoplasmic tail.
Ang II generated by ACE activity exerts its effects by binding to
angiotensin II receptors, type 1 and type 2; AGTR1 is the major mediator
of physiological effects of Ang II (vasoconstriction,
hypertrophy,catecholamine liberation at sympathetic nerve endings).
Both AGTR1 and AGTR2 are transmembrane receptors, comprising
seven membrane-spanning domains, and are coupled to G-proteins.
The ACE gene polymorphism was first reported by Rigat et al in a
study that addressed the role of the ACE gene in the genetic control of
plasma ACE levels18. Normally, plasma ACE levels show marked
interindividual variation but appear to be remarkably stable when
measured repeatedly in the same subject. The normal ranges for plasma
ACE levels and the units of measurement depend on the detection
method used. Rigat et al used direct radioimmunoassay measurement of
the enzyme (in µg/L); subsequently, functional assays using
spectrophotometric measurements (in U/L) have been used. Reference
ranges for each method must be established in the testing laboratory.
A current and widely used method is a spectrophotometric method
using the synthetic tripeptide substrate N-[3-(2-furyl)acryloyl]-L-
phenyl-alanylglycylglycine (FAPGG). The normal ranges are age-
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dependent and vary widely in adults (8–52 U/L). The polymorphism
discovered by Rigat et al is of the insertion/deletion type; the two ACE
alleles differ in size because of the insertion of a 287-bp DNA sequence
in intron 16 of the ACE gene74. The ACE polymorphism was initially
detected by restriction fragment length polymorphism (RFLP) analysis
and Southern hybridization with a human ACE cDNA probe94.
Subsequent studies of ACE polymorphism and disease associations used
polymerase chain reaction (PCR) for genomic DNA amplification. The
first PCR-based detection of the I/D ACE polymorphism (Fig-12) was
reported by Rigat et al74 who used a set of primers flanking the insertion
sequence; the generated amplicons corresponding to the I and D alleles
differ in size by the length of insertion sequence (ie, 287 bp) and allow
discrimination between the three genotypes: II, ID, and DD.
Parving et al. observed that the deletion allele of the ACE
polymorphism reduces the long-term beneficial effect of ACE inhibition
on the progression of overt diabetic nephropathy in patients with
diabetes95,96. In contrast, long-term treatment with the angiotensin II-
receptor blocker losartan induced a similar rate of decline in glomerular
filtration rate (GFR) .
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Based on a large, double-blind, randomized study comparing the
renoprotective effects of losartan versus placebo on top of conventional
blood pressure-lowering drugs in proteinuric type 2 diabetic patients, we
demonstrated that the deletion allele of the ACE gene had a harmful
impact on the composite endpoint of doubling of baseline serum
creatinine concentration, ESRD, or death. The D allele carriers had the
worst renal prognosis in all ethnic groups. It should be stressed that
demographic data, clinical history, and laboratory variables at baseline
by genotype were similar between the losartan and placebo groups with
the exception of proteinuria in the II genotype group. The beneficial
effects of losartan were greatest in the ACE/DD group and intermediate
in the ID group for nearly all endpoints, a trend suggesting a quantitative
interaction between losartan treatment and ACE/ID genotype on
progression  of  renal  disease.  In  agreement  with  a  previous  analysis  of
the RENAAL study, losartan exhibited renoprotection in all ethnic
groups97. The treatment-ACE-genotype interaction was significant for
the  risk  reduction  of  the  ESRD  endpoint.  The  major  novel  clinical
importance of the above  study is that those patients who have the
greatest need for renoprotective treatment have the best effect of
losartan  (DD  and  ID),  whereas  those  patients  with  a  better  renal
prognosis (II) also derived renal benefit. The finding of similar values
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for serum creatinine and albumin/creatinine ratio at baseline in the three
genotype groups may well be due to previous renoprotective treatment,
which according to the present analysis mitigated differences observed
in patients receiving RAAS blockade.
Effect of Genotype on Enzymatic Levels:
The ACE DD genotype is associated with increased circulating
ACE levels, which are generally two times as high as those found for II
genotypes; ID heterozygotes are associated with intermediate ACE
levels98(Fig-11). This relationship of D allele dose and enzymatic levels,
originally reported by Rigat et al, was repeatedly confirmed by other
studies, for both circulating and cellular ACE18,99-101. Increased
conversion of angiotensin I to angiotensin II, secondary to the higher
ACE concentrations, has been suggested to be a mechanism underlying
differences in cardiovascular and renal function/prognosis in subjects
with the DDgenotype compared with the II genotype102,103. However,
because the ACE I/D polymorphism is intronic, the mechanism of ACE
overexpression in subjects with DD genotype is unclear. It is thought to
be in linkage disequilibrium with a functional mutation in the gene19.
Figure-11
EFFECT   OF ACE GENE POLYMORPHISM
Figure - 12
ACE GENE SHOWING INTRON 16 THE SITE OF
INSERTION DELETION POLYMORPHISM
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Ang II, superoxide anions, and Inflammation:
Reactive oxygen species (ROS), generated by the membrane-
bound NADPH-oxidase system104 (Fig-13) and stimulated by Ang II via
its AT1-receptor, seem to be a pivotal step in glomeulosclerosis; it is
possible that this relationship is the result of tight linkage to another
locus involved in the regulation of ACE gene expression105. DD
genotype associated with increased ACE activity results in increased
Ang II production and thereby it contributes to glomerulosclerosis.
Griendling et al. first demonstrated that Ang II stimulates the generation
of ROS in vascular cells and macrophages, which are known activators
for cytoplasmic signaling cascades such as nuclear factor-kB (NF-kB),
mitogen-activated protein (MAP) kinases, or the Janus tyrosine kinases
(JAK)/signal transducers and activators of transcription (STAT)
cascade106,107. Together, these mechanisms may enhance oxidative stress
within the vascular wall and lead to the activation of redox-sensitive
genes, such as those for proinflammatory cytokines108. These
observations suggest that Ang II may, via redox-sensitive mechanisms,
activate IL-6 synthesis and release. Moreover, recent observations
indicate that proinflammatory eicosanoids, such as leukotriene B4 or
thromboxanes, are involved in AT1-receptor-dependent NADPH-
Figure-13
ANGIOTENSIN II IN FREE RADICAL PRODUCTION AND INFLAMMATION
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oxidase activation. This latter pathway does not only link inflammation
with the RAS but also plays a critical role based on its vasoconstrictive
and mitogenic potencies.
Other diseases associated with ACE gene polymorphisms :
ACE polymorphism and Coronary artery disease:
AGTR1 is the principal receptor mediating Ang II cardiac and
circulatory effects. Cardiac effects include direct inotropic activity
resulting in increased myocardial contraction, as well as cell growth and
proliferation, resulting in cardiac remodelling, hypertrophy, and
ventricular dilatation93. AGTR2 appears to be the dominant receptor in
both atrial and ventricular myocardium. Ang II can also be generated in
the tissues, including myocardium, by pathways other than RAS; non-
RAS pathways involve nonspecific carboxypeptidases and
chymotrypsin-like proteinases. An example of one of these is chymase
(serine-proteinase), which catalyzes an efficient Ang II generation at
tissue levels. Production of Ang II by these non-RAS alternative
pathways is not inhibited by therapy with ACE inhibitors. The chymase
pathway has been demonstrated in various cell types, including
myocardium, endothelial cells, and mast cells109. Chymase levels have
Figure-14
THE RAS AND KININ SYSTEM
38
been found higher in the ventricles than in the atria, and ventricle levels
do not appear to change significantly in heart failure109. Deletion
polymorphism in the for angiotensin converting enzyme is a potent risk
factor for myocardial infarction100.
The interaction between ROS, inflammatory cells, and the RAS
seemed to be important not only for the development of acute coronary
syndrome, but also for the progression of atherosclerosis . With regard
to the development of atherosclerotic lesions, evidence from other
animal models, including rodents and primates, shows that ACE
inhibition may reduce the extent of vascular lesions110-112.
Additional mechanisms by which the RAS via Ang II may
enhance the development of atherosclerosis involve the activation of
thrombosis pathways via PAI-1 113,114 or  the  stimulation  of  pro-
inflammatory cytokines. Diet et al.115 first demonstrated that Ang II–
forming protease ACE is expressed in human atherosclerotic plaques.
The authors demonstrated that in early- and intermediate-stage
atherosclerotic lesions, ACE was predominantly expressed in lipid-laden
macrophages (similarly to pro-inflammatory cytokines) whereas in
advanced lesions ACE was predominantly localized throughout the
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plaques microvasculature112. Potter et al. further demonstrated that lipid-
laden macrophages contain Ang II in a primate model of atherosclerosis.
In humans, at least two major enzymes, ACE and chymase, are
involved in the conversion of Ang I to Ang II and may contribute to
Ang II formation in coronary arteries. Further investigations
demonstrated that in normal and atheromatous coronary artery segments
of patients dying of noncardiovascular diseases that only ACE, but not
chymase, was co localized with Ang II in the intima of stable
atherosclerotic plaques. These findings suggest that ACE is apparently
the primary source of Ang II in atherosclerotic human coronary arteries.
Interestingly, Hoshida et al. demonstrated that tissue ACE activity is
selectively upregulated in patients with ACS but serum-ACE activity is
not. These observations suggest that tissue-ACE activity may represent
an important regulator of Ang II formation at the atherosclerotic lesion.
ACE Polymorphism and Venous Thrombosis
The DD genotype was found as a potent risk factor for thrombosis
in patients undergoing total hip arthroplasty116. In a case-controlled
study, Philipp et al investigated the association of ACE polymorphism,
with postoperative venous thrombosis. The plasma ACE levels in this
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study showed  the  same  pattern  previously  reported  by  others,  with the
highest values in DD patients, intermediate values in ID heterozygotes,
and the lowest values in II patients116. Another study that showed an
association between the DD genotype and an increased risk of venous
thrombosis  was  reported  by  Dilley  et  al117 for an African-American
population, with a threefold relative risk in men but not in women.
ACE Polymorphism and Coronary Restenosis after Stent
Implantation
Because RAS has been implicated in the development of
neointimal hyperplasia,118 ACE  activity  is  a  crucial  step  for  the  RAS
pathway, and the resulting increased generation of Ang II is a potent
growth factor for smooth muscle cells119, the hypothesis has been
advanced that genetic factors affecting RAS and particularly ACE gene
expression may be important in pathogenesis of coronary restenosis after
stenting. Indirect experimental evidence was obtained by demonstrating
that ACE inhibitors block neointimal thickening after arterial balloon
denudation in rats, guinea pigs, and rabbits120,121. The clinical relation
between restenosis after coronary stenting and ACE polymorphism was
investigated by Amant et al122 ;  the  association  of  the  number  of  D
alleles and poststent restenosis was independent of other risk factors122.
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The increased ACE activity due to the presence of the D allele, mainly
in the homozygous state, may account for the higher degree of coronary
neointimal thickening found in these patients122.
ACE Polymorphism and Hypertension
The association between ACE polymorphism and essential
hypertension is controversial. A significant association of the ACE gene
D allele with essential hypertension was documented in the African-
American (Duru et al., 1994), Chinese (Chiang et al., 1996), and
Japanese populations(Morise et al., 1994; Nakano et al., 1998). On the
other hand,the I allele was associated with high blood pressure in an
Australian population with strong evidence of familial hypertension
(Zee et al., 1992). It has been suggested that the population
heterogeneity in the association of ACE I/D polymorphism with
essential hypertension may be due to significant variations of population
backgrounds (Barley et al.,1994). Response to ACE inhibitors in
hypertensive patients appears to be determined at least in part by the
ACE genotype in the study of Ohmichi et al123.
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ACE polymorphism and breast cancer:
Evidence from animal models has suggested that angiotensin II
stimulates neovascularisation by promoting arteriolar smooth muscle
cell proliferation, and this has led to increased interest in the role that
angiotensin II may play a role in promoting angiogenesis in neoplastic
growth. In addition, angiotensin II may act as a mitotic factor by
inducing or regulating gene expression in cell cycle progression, and
angiotensin II receptor blockade effectively reduced transforming
growth factor ß1-dependent tumor progression in vivo . Captopril, a
prototype ACE inhibitor, has been shown to inhibit proliferation in a
variety of cell types, including human breast cancer cells123-126, and  to
reduce tumour growth in experimental models of cancer127.
Ace polymorphism was also studied in other diseases like
cardiomyopathy, stroke, Alzheimer’s disease, Systemic Sclerosis.
AIM OF THE
STUDY
43
AIMS AND OBJECTIVES
Diabetic nephropathy is a common cause of chronic kidney
disease especially in developing countries. It is a major contributor to
mortality in patients with type 2 diabetes mellitus. Genetic factors
appear to play an important role in susceptibility to diabetic nephropathy
because  it affects only one third of subjects. The knowledge of genetic
factors of diabetic nephropathy may help in explaining the molecular
basis of this disorder and in designing prevention and treatment
methods. Literature evidences point to the role of ACE gene I/D
polymorphism in the causation of glomerulosclerosis .Even though ACE
gene polymorphism is located in intron 16 of ACE gene, it is thought to
be in linkage disequilibrium with another functional mutation in the
gene. The differences in the degree of linkage disequilibrium between
this quantitative trait locus and I/D polymorphism are cited as a reason
for the differences in the associations of the polymorphisms with
diabetic nephropathy in different populations.
The aim of the study is
1  To find out distribution of ACE gene polymorphism among  healthy
controls ,  type 2  diabetic  patients  with  and  without  nephropathy.
2 To assess serum ACE activity among study groups and correlate with
the genotype .
MATERIALS AND
METHODS
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MATERIALS AND METHODS
This is a case-control study and was conducted after obtaining
ethical committee clearance. The study was carried out during the period
April 2011- October 2011 at Madras medical college and Rajiv Gandhi
government general hospital.
Study population:
CASES:
60 unrelated type 2 diabetic patients with duration of diabetes
more than five years attending diabetic outpatient department of our
hospital were included in the study after obtaining consent and were
categorised into
Group 1A:
30 (14 males, 16 females) type 2 diabetics with nephropathy and
Group 1B:
30 (11 males, 19 females) type 2 diabetics without nephropathy
based on the early morning urine albumin creatinine ratio (ACR). Urine
ACR was estimated with three times in a six month period and patients
who tested positive on two out of three measurements were included in
the diabetic nephropathy group.
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Patients with Urine Albumin Creatinine ratio of
                              > 23 mg/g of creatinine for males and
                              > 32 mg/g of creatinine for females128
were included in the nephropathy group.
Exclusion criteria:
? Known hypertensives on treatment
? Those who had BP > 140/90 mmHg
? Known heart disease patients
? Those who are on ACE inhibitors were excluded from the
study.
CONTROLS:
30 age and sex (15 males and 15 females) matched healthy
individuals attending master health check- up were selected as controls.
Sample collection:
Blood samples:
Blood was collected after an overnight fast of 8-12 hrs. About
5mL of blood was drawn from the cubital vein of the subjects. 2 mL was
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transferred into EDTA tubes and 3 mL into plain tubes. The blood
samples were analysed on the same day within an hour of collection.
DNA  extraction  was  done  on  the  same  day  and  extracted  DNA
stored at -20°C. Also 1mL of serum transferred into 1.5mL eppendorf
was stored at -20°C for measuring ACE activity.
Urine samples:
Early morning urine samples were collected in sterile plastic
containers and Albumin Creatinine ratio was estimated.
METHODS:
BUFFY COAT SEPARATION
Buffy coat was separated by centrifugation of EDTA tubes at
2000 revolutions  per minute for 20 minutes. Buffy coat was transferred
to 2mL eppendorf and was used for DNA extraction.
DNA EXTRACTION BY MODIFIED HIGH SALT METHOD129
RBC Lysis:
? 400µL of buffy coat in a 2mL eppendorf is mixed with 1.6mL of
0.17M ammonium chloride and mixed by inversion until red cells
are lysed for about 10 minutes
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? The cells are centrifuged at 4000rpm for 10minutes.
? The white cell pellet is washed with 800µL of 0.17M ammonium
chloride solution. The procedure is repeated till a clear white cell
pellet is obtained.
WBC Lysis
? To the pellet 500 µL of TKM I solution is added. It is centrifuged
at 10,000rpm for 10minutes.
Nuclear Lysis
? Discard  the  supernatant.  To  the  pellet  add  500  µL  of  TKM  II
solution. To that add 300 µL of 6M Nacl and 50 µL of 10% SDS.
? Mix well (vortex), Centrifuge at 10,000 rpm for 10 minutes.
? Save the supernatant. Transfer it to 1.5mL eppendorf.
DNA Precipitation
? To the supernatant double the volume of 100% ethanol is added.
? The sample is stored at -20?C for 1 hour.
? Then it is centrifuged at 10,000 rpm for 20minutes at 4?C in a
refrigerated centrifuge.
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? The supernatant is discarded. To this 500 µL of 70% ethanol is
added. The pellet is mixed and centrifuged at 10,000 rpm for
10minutes at 4?C.
? Supernatant is discarded and the pellet is air dried.
Storage
? To the pellet 30 µL of LTE buffer is added and the extracted
DNA is stored at -20?C for future use.
Identification
? Extracted DNA was identified by 0.8% agarose gel
electrophoresis with a constant voltage of 7V/ cm and comparison
with a known molecular weight 1kb DNA ladder.Figure:
Concentration of extracted DNA:
? Concentration of extracted DNA was estimated using UV
spectrophotometer at 260 nm.
? Concentration was calculated using the formula :
1 OD is equivalent to 50 µg/mL.
Conc. of DNA = absorbance X 50 µg/mL X dilution factor
                         =  y X 50 X 100 ng/µL
? Purity of extracted DNA was assessed by 260nm/280nm ratio.
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Estimation of Fasting plasma glucose:
Method: Glucose oxidase peroxidase (GOD/POD), Enzymatic method
Principle:
          Glucose oxidase
       Glucose +   O2                                             Gluconic acid  +  H2O2
      Peroxidase
H2O2 + Phenolic compound        Pink coloured complex
         +4aminoantipyrine                                             +2H2O
            The intensity of pink coloured compound is proportional to
glucose concentration and was measured at 505nm.
Procedure:
To  1  ml  of  working  reagent,  10  µL  of  plasma  was  added  and
incubated at 37°C for 15 min and absorbance was measured at 505nm.
Reference range : Fasting plasma glucose - ?  70 - 100 mg/dL
Estimation of Blood Urea:
Method : GLDH method, Enzymatic method
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Principle:
The test is performed as a kinetic assay in which the initial rate of
the reaction is linear for a limited period of time.
Urease
Urea + H2O                                        2NH4 + CO2
      GLDH
NH4 + NADH + H + + 2-Oxoglutarate   Glutamate + NAD+
The initial rate of decrease in absorbance at 340 nm is
proportional to the urea concentration in the sample.
Procedure:
To 1 mL of working reagent 10 µL of sample or standard is
added. Absorbance is measured after 30 sec (A1) and 90 sec (A2).
Calculation:
  ?A Sample
     X   50 (Standard Conc) = mg/dL urea in the sample
?A Standard
Reference range: Normal blood urea = 15 to 40 mg/dL
Estimation of Serum Creatinine:
Method : Modified Jaffe’s Method.
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Principle:
Creatinine reacts with alkaline picrate to produce an orange-
yellow coloured complex (creatinine picrate). The absorbance of
orange-yellow colour formed is directly proportional to creatinine
concentration and is measured photometrically at 520 nm.
Procedure:
To 500 mL of working reagent 50 µL of serum sample or
standard is added and initial absorbance (A1) is measured at 20 sec and
final absorbance (A2) is measured at 80 sec after mixing.
Calculation:
?A = A2 – A2
    ?A of Test
Creatinine  =                          X   Concentration of Standard (2 mg/dl)
   (mg/dL)     ?A of Standard
Normal range : 0.6-1.2 mg/dL
Estimation of Urine Creatinine:
        Estimation of urine creatinine is done in the same method(
modified Jaffe’s) as serum creatinine measurement except for diluting
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the urine sample ten times and multiplying the obtained result with
dilution factor.
Normal Urine creatinine excretion is 1-2 g/day
Estimation of Urine Microalbumin :
Method: Immunoturbidimetry method.
Principle :
              Latex particles coated with specific antibodies anti-human
albumin are agglutinated when mixed with samples containing
microalbumin. The agglutination causes an absorbance change
dependent upon the µALB contents of the patient sample  and quantified
by comparison with a calibrator of known µALB concentration.
Procedure :
             To 1 mL of the working reagent 7µL of calibrator or sample is
added and absorbance measured immediately(A1)  and  after  2  min  (A2)
of sample addition. The temperature of the reagent and the reaction
mixture are maintained at 37°C.
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Calculations:
  (A2 - A1) sample
        X   Calibrator concentration  =   mg/L albumin
(A2 - A1) calibrator
Calibrator of concentration 64 mg /L was used.
Normal : 30 mg/24 hrs urine specimen
             20 mg/L in early morning sample
Estimation of Urine Albumin Creatinine Ratio (ACR) :
Urine microalbumin per gram of Creatinine excreted was
calculated for each patient sample.
ACR   ? 23 mg/g of creatinine for males and
? 32 mg/g of creatinine for females is considered as
nephropathy range.
Estimation of Serum ACE activity :
Method: Serum ACE activity was measured spectrophotometrically
at 340 nm.
Principle : The  following reaction is catalysed by ACE:
FAPGG                          FAP  + Glycylglycine
FAPGG ( N-[3-(2-furyl)acryloyl]-L-phenylalanylglycylglycine) is
hydrolysed to furylacryloylphenylalanine (FAP) and glycyl glycine.
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Hydrolysis of FAPGG results in a decrease in absorbance at 340 nm.
The ACE activity in the sample is determined by comparing the sample
reaction rate to that obtained with the ACE calibrator.
Procedure:
The temperature of the reaction mixture was maintained at 37°C.
           To  1  ml  of  ACE  reagent  100µL  of  calibrator  or  serum  sample
added, mixed well.
Constant temperature maintained using a water bath and after 5
min absorbance recorded which is the initial absorbance. Exactly after 5
min again absorbance was recorded. This is the final absorbance.
Calculation:
?A  per  5 min (Test) = Initial  A Test – Final  A Test
?A  per  5 min (Calibrator) = Initial A Calibrator – Final A Calibrator
                                ?A/5 min  of  Test
 ACE (U/L)  =                                             x     Activity of calibrator
                            ?A/5 min of  Calibrator
Absorbance values were calculated using  an ACE Calibrator with
an activity of 50µL at 37°C.
Normal range : 8 – 52 U/L at 37°C.
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POLYMERASE CHAIN REACTION
ACE gene was amplified using,
• Forward primer – 5’-CTGGAGACCACTCCCATCCTTTCT–3’ and
• Reverse primer – 5’-GATGTGGCCATCAATTCGTCAGAT – 3’
Primer Reconstitution
Primers are supplied in lyophilized form.
Autoclaved distilled water is used to prepare 100 × concentrations
i.e. 10times the molecular weight of primer is the volume of water
required to prepare 100 × concentrations which is 100µmolar solution.
? From this stock solution 10 × concentration is prepared as the
working solution for PCR.
MASTER MIX:
? Genei Red Dye master mix in the following composition was
used.
? Master Mix consists of a unique inert red dye in addition to basic
components necessary for PCR.
• Reaction buffer consisted of Tris Hcl -10mM at pH 8.3
                                               KCl - 50mM
• MgCl2 - 1.5mM acts as catalyst.
• dNTP’s were used in a concentration of 2.5mM each.
• Taq polymerase in a concentration of 1.5 U.
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? Primers  were  used  in  a  concentration  of  5  pmol  and  DNA  was
used in a concentration of 200ng.
? PCR  was  carried  out  in  a  reaction  volume  of  12.5  µL  with  the
following components;
• PCR master mix –  6.5 µL
• Forward primer –  0.5 µL
• Reverse prime –  0.5 µL
• DNA –  1.0µL
• Distilled water –  4.0 µL
• Total – 12.5 µL
? Amplification was carried out in an Mc Genei thermal cycler with
the following cycling conditions.
• Initial denaturation – 940 C -5min
• 30 cycles of
• Denaturation – 940C – 1 min
• Annealing - 580C – 1min
• Extension -720C – 1min
• Final extension at 720C - 10 min.
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? Amplified products 490 bp PCR for I allele and 190bp PCR
product for D allele was identified by agarose gel electrophoresis
by comparison with a known 100bp DNA ladder. Thus, each
DNA sample revealed one of three possible patterns after
electrophoresis: a 490 bp band (II genotype), a 190 bp band (DD
genotype), or both 490 and 190 bp bands (I/D genotype) Figure .
AGAROSE GEL ELECTROPHORESIS
? PCR product is run on agarose gel in a 50 mL agarose cast as
follows: 1g of agarose is weighed and dissolved in 50mL of TAE
buffer with a pH of 8.0.
? It is microwaved for 60 secs, cooled and 2.5 µL of ethidium
bromide (10mg/mL) is added. It is poured into a cast and allowed
to solidify for 15 min before it is kept in the electrophoresis tank.
? 8 µL of PCR product is loaded onto wells and 4 µL of 100bp
DNA ladder is loaded onto single well as a marker. It is
electrophoresed at 8V/cm for 45min and visualized under UV
illumination.
AGAROSE GEL ELECTROPHORESIS OF PCR PRODUCTS
Agarose gel electrophoresis of PCR products. Deleted allele has  190bp product,
Inserted allele has 490 bp product. Lane 1 shows ladder
(100,200,300,400,500,600,700,800,900,1000bp), lanes 2,4,5,6,8  shows both the products
indicating  ID genotype, lanes 7 shows only 190bp product indicating DD genotype, lane
3 shows only 490 bp product indicating II genotype.
1       2      3       4      5      6     7   8
490
bp
190
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STATISTICAL ANALYSIS
1.  Waist-Hip ratio, Fasting plasma glucose, Blood urea, Serum
creatinine, Urine microalbumin, Urine Creatinine and Urine
Albumin Creatinine ratio were compared between three study
groups by ANOVA.
2. ACE Genotype frequency distribution between cases and controls
were compared with ANOVA.
3. Odds ratio was calculated for ACE genotype distribution in the
study population.
4. Allele frequencies were calculated by allele counting.
5. ACEactivity was compared between the study groups by
ANOVA.
6. ACE activity for the ACE genotypes were compared by ANOVA.
Statistical analysis was done using SPSS software.
RESULTS
CASES - Group 1A – DIABETICS NEPHROPATHY
Sl.
No. Age Sex
Duration
of
diabetes
Waist
circum-
ference
(cm)
Hip
circum-
ference
(cm)
Waist
Hip
ratio
Fasting
Plasma
Glucose
(mg/dL)
Blood
Urea
(mg/dL)
S.Creati
nine
(mg/dL)
U.Crea
tinine
(g/dL)
U.MicroA
lbumin
(mg/L)
Albumin
creatinine
ratio (mg/g
of
creatinine)
ACE poly-
morphism
ACE
activity
(U/L)
1 65 M 6 80.5 90.5 0.89 162 18 0.9 0.8 149 186 DD 73
2 50 M 6 81.5 93.5 0.87 189 20 1 1.1 73 66 ID 52
3 55 M 6 77.5 86.5 0.9 104 25 1.1 1 76 76 ID 61
4 60 M 6 94.5 100.5 0.94 289 32 0.7 0.9 83 92 DD 115
5 52 M 6 70 88 0.8 129 20 1.1 0.9 39 43 ID 55
6 57 F 6 77 96 0.8 140 26 1.1 0.8 40 50 DD 81
7 50 M 6 78 92 0.85 308 26 0.9 1 39 39 II 41
8 53 F 7 92.5 95.5 0.97 85 40 0.8 1 100 100 DD 88
9 57 M 7 96.4 105 0.92 170 26 1 1 54 54 ID 57
10 59 F 8 101.5 117 0.87 157 52 1 1.3 109 84 DD 79
11 55 F 10 84 98 0.86 152 22 1.2 0.9 77 86 DD 97
12 65 F 10 83.5 95.5 0.87 127 29 0.9 0.9 43 48 ID 53
8 58 F 10 93.5 102.5 0.91 259 21 1 1 52 52 DD 81
14 60 F 10 89.5 98.5 0.91 164 20 0.8 1.9 86 43 II 16
15 60 F 10 86.5 92.5 0.94 270 37 0.8 0.9 85 94 DD 83
16 61 F 10 80.5 92.5 0.87 87 31 1.1 0.9 78 87 DD 67
17 50 F 10 81.5 92.5 0.88 286 52 0.9 0.8 34 42 DD 86
18 56 M 10 82 93 0.88 127 25 0.9 1.4 115 82 ID 61
19 45 F 10 86 98 0.88 214 28 1.1 1 125 125 DD 68
20 58 M 11 91.5 96.5 0.95 235 23 1 1.1 43 38 II 23
21 47 F 11 85 107 0.79 148 30 1 0.8 57 71 ID 56
22 53 M 12 96 100 0.96 187 25 0.9 1.1 132 120 II 34
23 63 F 12 92.5 102.5 0.9 138 24 1.1 1 54 54 DD 112
24 42 F 12 80 93 0.86 131 28 0.9 1.1 79 72 DD 72
25 62 M 13 83 92 0.9 88 22 1 0.8 45 56 ID 54
26 63 M 15 76.5 87.5 0.87 131 30 1.1 0.9 59 66 DD 76
27 65 F 15 78.5 98.5 0.8 204 26 0.9 1.2 108 90 ID 59
28 64 M 15 65.5 77.5 0.85 264 27 1.1 0.9 118 131 DD 70
29 61 M 15 102.5 109.5 0.94 88 38 1 0.8 41 51 DD 84
30 45 F 7 83 105 0.79 192 31 0.9 1 60 60 DD 68
CASES - Group 1B – DIABETICS WITHOUT NEPHROPATHY
Sl.
No. Age Sex
Duration
of
diabetes
Waist
circum-
ference
(cm)
Hip
circum-
ference
(cm)
Waist
Hip
ratio
Fasting
Plasma
Glucose
(mg/dL)
Blood
Urea
(mg/dL)
S.Creati
nine
(mg/dL)
U.Crea
tinine
(g/dL)
U.MicroA
lbumin
(mg/L)
Albumin
creatinine
ratio (mg/g
of
creatinine)
ACE poly-
morphism
ACE
activity
(U/L)
1 53 F 6 90 100 0.9 135 32 1 1.7 13 7.6 ID 53
2 60 F 6 91.5 112.5 0.81 110 22 0.8 1.1 10 9.5 ID 50
3 54 F 6 91.5 103.5 0.88 146 20 0.7 1 20 20 ID 60
4 40 F 6 95 105 0.9 123 22 0.8 0.9 20 22 ID 57
5 47 F 6 72 95 0.76 149 30 0.8 1.4 17 12 ID 52
6 57 M 7 90.5 96.5 0.94 166 34 1.1 1 19 19 II 28
7 55 F 7 91.5 100.5 0.91 217 28 1 0.8 12 15 DD 61
8 43 M 7 84.5 94.5 0.89 132 37 1.1 1 5 5 II 18
9 65 M 7 85.5 94.5 0.9 475 30 1 1.3 26 20 DD 65
10 54 F 7 92.5 101.5 0.91 130 25 0.8 0.9 12 13 II 32
11 53 F 7 80 96 0.83 126 21 1 0.8 2.4 3 ID 48
12 57 F 7 82 97 0.85 100 33 0.9 1.4 22 15 II 7
13 47 M 7 82 93 0.88 142 28 1 1.7 10 5 ID 54
14 48 M 8 80 93 0.86 184 22 1 1.3 18 14 II 26
15 55 F 8 76 95 0.8 128 24 1 0.9 8.4 10 ID 64
16 48 M 8 86 97 0.89 139 26 1 0.9 10 11 II 22
17 60 F 9 106.5 115.5 0.92 123 20 0.8 0.8 16 20 ID 75
18 60 F 9 91 106.5 0.85 239 19 0.8 1.2 13 11 II 12
19 49 M 9 93.5 98.5 0.95 160 24 1.1 1.7 17 10 DD 69
20 64 M 10 73.5 81.5 0.9 96 37 1.1 0.8 9 1 ID 51
21 40 F 10 92.5 102.5 0.9 153 23 0.8 0.8 7 8 II 34
22 59 F 10 83.5 103.5 0.81 76 22 0.9 1.4 18 24 ID 55
23 40 M 10 93.5 94.5 0.99 125 20 1.1 1.5 15 10 II 21
24 48 F 10 90.5 111.5 0.81 135 26 0.8 1.1 21 19 II 13
25 55 F 10 100 114 0.88 136 26 1 1 22 22 DD 65
26 50 M 11 94.5 106.5 0.89 178 32 0.9 0.6 4.3 8 DD 80
27 56 F 11 88.5 101.5 0.87 206 38 0.8 0.8 14 18 II 10
28 61 M 11 80 88 0.9 128 22 1 1 17 17 ID 51
29 45 F 15 85 99.5 0.85 120 40 1.1 0.9 4.8 9 ID 56
30 60 F 15 66.5 73.5 0.9 300 28 1 0.8 10 13 DD 70
CONTROLS
Sl.
No. Age Sex
Waist
circum-
ference
(cm)
Hip
circum-
ference
(cm)
Waist
Hip ratio
Fasting
Plasma
Glucose
(mg/dL)
Blood
Urea
(mg/dL)
S.Creatin
ine
(mg/dL)
U.Creatin
ine
(g/dL)
U.MicroA
lbumin
(mg/L)
Albumin
creatinine
ratio (mg/g of
creatinine)
ACE poly-
morphism
ACE
activity
(U/L)
1 46 M 78 100 0.78 100 24 0.9 0.9 10 11 ID 48
2 42 F 74 90 0.82 82 28 0.9 1 4.5 4.5 II 20
3 43 M 100 112.5 0.89 91 21 1 1.1 7 6 ID 52
4 51 M 83 94 0.88 60 32 1 1.4 18 13 DD 47
5 55 M 80 97 0.82 112 20 0.8 1 12 12 ID 55
6 60 M 87 91 0.96 101 40 1.1 1.6 16 10 II 9
7 50 F 89 104 0.86 95 22 0.7 0.8 10 12.5 ID 50
8 63 M 85 91 0.93 110 26 0.9 1.2 19 16 II 33
9 59 F 89 102 0.87 112 25 0.9 1 15 15 DD 71
10 52 F 84 102 0.82 84 20 0.9 0.8 2 2.5 II 15
11 53 F 92.5 103.5 0.89 96 27 1 0.8 9 11 II 26
12 55 M 76 87 0.87 66 36 0.9 1 7.4 7.4 ID 52
13 48 F 96 115 0.83 114 30 0.8 0.9 3.6 4 ID 57
14 51 M 93 106 0.88 93 31 0.9 1 9 9 ID 55
15 54 F 99 129 0.77 85 30 0.8 0.8 2.4 3 II 19
16 47 F 90 110 0.82 70 20 1 2 16.8 8.4 II 23
17 55 M 63 82 0.77 66 28 0.8 1.5 21 14 ID 55
18 55 M 68 102 0.67 80 24 0.9 1 6 6 ID 57
19 51 F 86 103 0.83 95 29 0.8 0.9 13 14 ID 50
20 50 M 71 93 0.76 78 34 0.9 1.1 7 6 II 34
21 54 M 80 96 0.83 88 30 0.8 0.8 5 6 II 22
22 52 M 92 105 0.88 106 23 0.9 1.2 20 16 ID 49
23 43 F 92 111 0.83 62 37 1 0.7 6 8.6 ID 64
24 57 F 78 95 0.82 110 24 0.8 2 10 5 II 30
25 50 F 74 95 0.78 82 25 0.8 0.8 4 5 ID 58
26 62 F 91 115 0.79 80 36 1 2.2 18 8 II 25
27 61 M 95 112 0.85 101 26 0.9 0.8 4 5 ID 53
28 55 M 90 106 0.85 79 34 0.8 1.3 17 13 II 11
29 54 F 88 98 0.90 91 27 1 0.9 13 14 ID 54
30 56 F 91 107 0.85 83 33 1 1 3 3 ID 56
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RESULTS
Table 1:
Shows Waist-hip ratio, Fasting plasma glucose, Blood urea,
Serum creatinine, Urine microalbumin, Urine Creatinine and Urine
albumin creatinine ratio were compared between cases and controls by
ANOVA.
Waist-Hip ratio:
The mean Waist-Hip ratio for Group 1A (diabetics with
nephropathy) was 0.88 while that of Group 1B (diabetics without
nephropathy) was 0.87 and that of controls was 0.84. Both the study
groups (cases) showed slightly increased waist-hip ratio when compared
with controls and the difference is statistically significant(P
value=0.002).
Fasting plasma glucose:
The mean fasting plasma glucose for Group 1A was 174 mg/dL
while  that  of  Group  1B  was  159  mg/dL  and  that  of  controls  was  89
mg/dL. The difference between the groups was found to be statistically
significant (P value= 0.000).
TABLE - 1
Comparison of parameters in cases and controls
Variables
Cases
Controls P valueGroup1A
Diabetics with
nephropathy
Group1B
Diabetics without
nephropathy
Waist-Hip
circumference
0.88± 0.050 0.87±0.048 0.83± 0.057 0.002 – S
Fasting plasma
glucose mg/dL
174.17±65.57 159.23±74.74 89.07±15.48 0.000 – S
Blood Urea mg/dL 28.47±8.32 27.03±6.04 28.07±5.46 0.697 – NS
Serum Creatinine
mg/dL
0.973±0.12 0.940±0.12 0.897±0.09 0.032 – S
Urine
Microalbumin
mg/L
75.10±31.992 13.76±6.03
10.29±5.882 0.000-S
Urine Creatinine
g/L
1.01±0.22 1.08±0.31 1.12±0.39 0.384-NS
Urine Albumin
Creatinine ratio
mg/g of creatinine
75.27±33.11 13.04±6.1 8.96±4.23 0.000 – S
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Blood urea:
               The mean Blood urea for group 1A was 28 mg/dL while that of
group 1B was 27mg/dL and that of controls was 28 mg/dL. The blood
urea values are within normal reference range and there was no
statistical significance between the groups(p value=0.697).
Serum creatinine:
              The mean serum creatinine value for group 1A was 0.97 mg/dL
while that of group 1B was 0.94 mg/dL and that of controls was 0.90
mg/dL. Even though the difference is statistically significant (p
value=0.032) the serum creatinine values were found to be within
normal limits in the study groups.
Urine microalbumin:
               Urine microalbumin – mean value for group 1A was 75mg/L
while that for group 1B was 14mg/L and that of controls was 10mg/L .
It is found that urine microalbumin levels are elevated in diabetic
nephropathy group and the difference was found to be highly significant
statistically (P value=0.000).
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Urine creatinine:
The mean value for group 1A was 1.01 g/L while that of group
1B was 1.08 g/L and that of controls was 1.12 g/L and there was no
statistical difference between the groups (p value=0.384).
Urine Albumin Creatinine ratio:
Urine Albumin Creatinine ratio – mean value of group 1A was
75mg/g of creatinine while that of group 1B was 13 mg/g of creatinine
and that of controls was 9 mg/g of creatinine and statistically the
difference was found to be highly significant(p value=0.000). The
results show that urine albumin creatinine ratio is highly elevated in
diabetic nephropathy group.
Table 2
Shows the genotype distribution of ACE gene in Group1A (type 2
diabetic nephropathy), Group 1B (diabetics without nephropathy) and
controls.
? DD genotype was more frequently distributed among  diabetic
nephropathy patients 17(56.7%) compared to diabetics without
nephropathy 6(20.0%) and controls 2(6.7%).  There was a significant
TABLE – 2
ACE genotype distribution in study population
Genotype
Group1A-
DM with
nephropathy
30
Group1B-
DM without
nephropathy
30
Controls
30
P value
DD 17(56.7%) 6(20.0%) 2(6.7%)
0.000- S
ID 9(30.0%) 13(43.3%) 16(53.3%)
II 4(13.3%) 11(36.7%) 12( 40.0%)
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
Dm with
nephropathy DM without
Nephropathy Control
ACE GENOTYPE FREQUENCY
DD
ID
II
57%30%
13%
ACE genotype distribution in group
1A (diabetics with nephropathy)
DD ID II
20%
43%
37%
ACE genotype distribution in group
1B (diabetics without nephropathy)
DD ID II
7%
53%
40%
ACE genotype distribution in
CONTROL GROUP
DD ID II
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difference in the distribution of DD genotype between diabetic
nephropathy cases and the other two groups as indicated by the P
value (0.000).
? While ID and II genotypes were distributed more in the diabetics
without nephropathy and in controls when compared to diabetic
nephropathy population.
ACE genotype distribution was in agreement with the Hardy-
Weinberg expectations.
Table 3
             Shows the Odds ratio for ACE genotypes among the study
groups.
? The odds ratio for DD genotype between group 1A and group 1B
was found as 5.2 and Odds ratio of 3.5 between group 1B and
controls and odds ratio of 18 for group 1A and controls.
? The results show that DD genotype has 18 times higher association
with diabetic nephropathy compared to controls.
? Other genotypes do not show significant association.
TABLE – 3
ODDS RATIO for ACE genotypes between study groups
Genotype
Group 1A(Diabetic
nepropathy) Vs
Group 1B(Diabetics
without
nephropathy)
Group1B(Diabetics
without
nephropathy) Vs
controls
Group 1A(Diabetic
nepropathy) Vs
controls
DD 5.2 3.5 18.30
ID 0.56 0.67 0.38
II 0.27 0.87 0.23
0
2
4
6
8
10
12
14
16
18
20
DN & DM DM& controls DN & controls
O
D
D
S 
R
A
TI
O
GROUPS
ODDS RATIO FOR ACE GENOTYPE IN
THREE GROUPS
DD
ID
II
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Table 4
          Shows the Allele distribution of ACE gene between diabetic
nephropathy cases and controls.
? It is found that the D+ allele was distributed more commonly in cases
. the odds ratio was found to be 4 and p value also significant.
? D+ allele occurs more frequently in cases than controls.
Table 5
Shows serum ACE activity among the three groups.
? It is found that serum ACE activity for group 1A(diabetics with
nephropathy) was  67 U/L while that of group 1B was 45 U/L and
that of controls was 41U/L.
? P value is 0.000, indicates that the difference is statistically
significant.
? Our study results indicate that serum ACE activity is elevated in
diabetic nephropathy group compared to other groups.
TABLE-4
Distribution of D+ allele in Diabetic nephropathy cases and controls
Allele
Group 1A-Diabetic
Nephropathy Cases Controls P Value
D+ 26(86.6%) 18(60%) 0.020
Odds ratio= 4
D- 4(13.3%) 12(40%)
0
5
10
15
20
25
30
Diabetic Nephropathy
Cases
Controls
N
U
M
BE
R 
O
F 
CA
SE
S
GROUPS
D+ & D- allele distribution in
DN & CONTROLS
D+
D-
TABLE-5
Serum ACE activity in study groups
Group 1A -DM
with
nephropathy
Group 1B-DM
without
nephropathy
Control
P value
Serum ACE
activity U/L
(Normal range
is 8-52)
67.40 ±22.478 45.30 ± 21.324 41.67 ± 17.440
0.000-S
0
10
20
30
40
50
60
70
DM with
nephropathy
DM without
nephropathy
controls
Se
ru
m
 A
CE
 a
ct
iv
it
yU
/L
groups
Serum ACEactivity in study groups
DM with nephropathy
DM without nephropathy
controls
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? The ACE activity of Group 1B and Control are within the normal
range but that of Group 1A (diabetic nephropathy) is well elevated
above upper limit of normal.
Table 6
Shows the association of ACE genotype with the phenotype(ACE
activity)
? ACE genotype and its phenotype(ACE activity) were compared.
? It is observed that serum ACE activity is elevated in DD genotype
? Highest(73U/L) level of ACE activity in DD genotype,
lowest(22U/L) in II genotype and intermediate(55U/L) in ID
genotype  .
? P value =0.000 which is highly significant statistically.
TABLE-6
Genotype and Phenotype(ACE activity)
Genotype
ACE activity(U/L)
Normal range : 8-52
P value
DD 73.36±14.54
0.000-S
ID 55.49±5.65
II 22.61±8.65
0
10
20
30
40
50
60
70
80
DD ID II
Se
ru
m
 A
CE
 a
ct
iv
it
y 
U
/L
Genotypes
ACE  activity  & ACE genotype
ACE activity
DISCUSSION
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DISCUSSION
Long  term  type  2  diabetes  is  a  major  and  important  cause  of
nephropathy. Despite well known risk factors large variation in
prevalence among different diabetic populations and  clustering of
diabetic nephropathy in families5,6 suggest genetic factor involvement.
renin–angiotensin–aldosterone system(RAAS) plays a central role in the
regulation of blood pressure, sodium metabolism and renal
hemodynamics, with its actions mediated primarily by angiotensin II.
The gene encoding components of the RAAS,especially ACE gene is
extensively studied.
In our study we found that the urine microalbumin was elevated
but blood urea and serum creatinine were within the normal limits in
diabetic nephropathy patients. This indicates that these nephropathy
patients are in their early stage disease.
From our study we found a more frequent association of DD
genotype of ACE gene in diabetic nephropathy group patients (56.7%)
when compared to controls and type 2 diabetics without nephropathy.
The Odds ratio between diabetics with nephropathy and diabetics
without nephropathy was found to be 5 in our study. This is similar to
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studies done by Viswanathan et al, and Bhavani et al, who found
positive association between the D allele of the ACE gene
polymorphism and diabetic nephropathy in South Indian type 2 diabetic
patients. Whereas studies done in North Indian population by Ajay
kumar et al, and Prasad P.et al found there was no relation between ACE
gene polymorphism and development of diabetic nephropathy. It is
reported that the D polymorphism of ACE gene is associated with
susceptibility to diabetic nephropathy with more marked association
among type 2 diabetic Asians than in Caucasians130. Other studies have
shown  that  the  deletion  polymorphism  can  affect  both  the  risk  and
progression of diabetic nephropathy whereas Schmidt et al.
demonstrated that the deletion polymorphism may act on progression of
but not susceptibility to diabetic nephropathy131. Several Japanese
studies had also found the D allele to be an independent risk factor for
diabetic nephropathy in type 2 diabetic patients132-134. The odds ratio
noted in our study for the association of D+ allele with nephropathy was
found to be 4. In our study we found that ACE activity was
elevated in the diabetic nephropathy group with the mean value of 67
U/L while that of diabetics without nephropathy group it was 45 U/L
and  that  of  controls  was  41U/L.  The  difference  was  found  to  be
statistically significant(P value=0.000) between diabetic nephropathy
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cases and controls. The ACE gene polymorphism was first reported by
Rigat et al in a study that addressed the role of the ACE gene in the
genetic control of plasma ACE levels. The ACE DD genotype is
associated with increased circulating ACE levels, which are generally
two times as high as those found for II genotypes; ID heterozygotes are
associated with intermediate ACE levels18. This relationship of D allele
and enzymatic levels, originally reported by Rigat et al, was repeatedly
confirmed by other studies, for both circulating and cellular
ACE100,101,135. ACE gene polymorphism determines the serum and tissue
ACE activity in subjects with DD polymorphism (Malik et al., 1997).
However, because the ACE I/D polymorphism is intronic, the
mechanism of ACE overexpression in subjects with DD genotype is
unclear. It is thought to be in linkage disequilibrium with a functional
mutation in the gene19.
Highest(73U/L) level of ACE activity in DD genotype,
lowest(22U/L) in II genotype and intermediate(55U/L) in ID genotype
was observed in our study with significant statistical difference (p
value=0.000). These findings are in concordance with other studies.
CONCLUSION
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CONCLUSION
This study was conducted to find out the ACE gene
insertion(I)/deletion(D) polymorphism among diabetics with
nephropathy and without nephropathy. 30 cases of diabetics with
nephropathy were compared with 30 diabetics without nephropathy.
From our study we found that :
1.  Type 2 diabetics with nephropathy had a higher frequency of ACE
DD genotype  compared to diabetics without nephropathy and
controls.
2. Serum ACE activity is significantly elevated in Diabetic nephropathy
patients which is responsible for the nephropathic changes.
3. Serum ACE activity in diabetics without nephropathy is within the
reference range and is comparable with the control group.
4. The level of Serum ACE activity was highest in DD genotype,
lowest in II genotype and intermediate in ID genotype and hence DD
genotype is strongly associated with nephropathy.
5. DD genotype is an independant  risk factor for the development of
nephropathy.
FUTURE
PROSPECTS OF
THE STUDY
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SCOPE FOR FURTHER STUDY
Angiotensin converting enzyme(ACE) is known to catalyse the
conversion of Angiotensinogen to Angiotensin II which is responsible
for efferent arteriolar constriction. Hence elevated levels of ACE are
responsible for the pathogenesis of glomerulosclerosis leading to
nephropathy. The ACE gene polymorphism has been widely studied as
candidate gene in the development of diabetic nephropathy.
Studies have reported conflicting data regarding ACE/ID
polymorphism and the individual antiproteinuric response to ACE
inhibition. It is also reported that patients with  ACE DD genotype
showed poor response to ACE inhibition. The beneficial effects of
losartan were greatest in the ACE/DD group and intermediate in the ID
group  suggesting a quantitative interaction between losartan treatment
and ACE/ID genotype on progression of renal disease providing
renoprotection in all ethnic groups136.
In our study we have not confirmed the DD genotypes using
insertion specific primers to rule out the possibility of mistyping137 due
to  amplification  of  D  allele  and  the  DD  positive  cases  have  to  be
confirmed again by using another insertion specific primer.
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Future prospects:
1. ACE gene polymorphism screening can be done in families with
type 2 diabetes for risk of development of nephropathy.
2. ACE gene polymorphism screening can be done to monitor
progression of severity of nephropathy in diabetics.
3. Screening for personalising treatment with ACE inhibitors or
Angiotensin receptor blockers.
4. Long term renoprotective effects with angiotensin receptor
blockers have to be evaluated.
5. ACE DD genotype can be confirmed with insertion specific
primers to rule out the possibility of mistyping due to
amplification of D allele.
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